author-photo

Juneko E. Grilley-Olson

University of North Carolina at Chapel Hill

110

Papers

1339

Citations

Citation Trend

Filter By

Papers (65) Sort By

Journal Conference Others

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.

2021 Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.

2020 American Journal of Dermatopathology
Show All
- Source
- Cite
- Save
Citations (1)
EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

2020 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 5535: SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors

2020 Immunology
Show All
- Source
- Cite
- Save
Citations (4)
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Progression-free survival, overall survival and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab

2020 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (2)
Abstract CT046: Predictive biomarkers and pharmacodynamic changes in tumor RNA expression in a phase I study of anti PD-1 monoclonal antibody PF-06801591

2019 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (48)